Ç׿øÁ¦½Ã¼¼Æ÷¸¦ ÀÌ¿ëÇÑ ¾Ï Ä¡·áÁ¦ °³¹ßÀü¸Á
The Prospective of Antigen-presenting Cells in Cancer Immunotherapy

Çѱ¹»ý¹°°øÇÐȸÁö 2004³â 19±Ç 6È£ p.415 ~ p.420

½ÉµÎÈñ(Sim Doo-Hee) - ½Å¶ó´ëÇб³ °ø°ú´ëÇÐ »ý¸í°øÇаú
ÀÌÀçÈ­(Lee Jae-Hwa) - ½Å¶ó´ëÇб³ °ø°ú´ëÇÐ »ý¸í°øÇаú

Abstract

Àü ¼¼°èÀûÀ¸·Î ¾ÏÀÇ ¹ßº´·üÀÇ Áõ°¡ÇÏ°í ÀÖ°í ¶ÇÇÑ ±× ¼ö´Â Çظ¶´Ù Áõ°¡ÇÏ´Â ½ÇÁ¤ÀÌ´Ù. ¾ÏÀº ¼ºÀå¾ç»ó¿¡ µû¶ó ¾Ç¼ºÁ¾¾ç°ú ¾ç¼ºÁ¾¾çÀ¸·Î ³ª´µ´Âµ¥ ¾ÏÀ¸·Î ±¸ºÐµÇ´Â ¾Ç¼ºÁ¾¾çÀ» Ä¡·áÇϱâ À§ÇÑ ¿©·¯ °¡Áö Ä¡·á¹ýµéÀÌ ½ÃÇàµÇ°í ¶Ç °³¹ßµÇ°í ÀÖ´Ù. ±×Áß¿¡¼­ dendritic cells (DCs)´Â ÀÎü ³» ¸é¿ª¹ÝÀÀÀ» ÀÌ¿ëÇÏ¿© ¾ÏÀ» Ä¡·áÇÏ´Â ¹æ¹ýÀ¸·Î ÀûÀÀ¸é¿ª¿¡ °ü¿©ÇÏ´Â cytotoxic T cell (CTL)¿¡ Ç׿øÀ» Á¦½ÃÇÏ¿© CTL·Î ÇÏ¿©±Ý Á¾¾ç¼¼Æ÷¸¦ Á÷Á¢ÀûÀ¸·Î °ø°ÝÇϵµ·Ï µµ¿òÀ» ÁÖ´Â ¿ªÇÒÀ» ÇÑ´Ù. ±×·¯³ª ¿©±â¿¡´Â ¿©·¯ °¡Áö ´ÜÁ¡ÀÌ ÀÖ´Ù. ÀÌ ´ÜÁ¡À» º¸¿ÏÇϱâ À§ÇÑ »õ·Î¿î ¹æ¹ýÀ¸·Î artificial antigen-presenting cell (aAPC)À» ÀÌ¿ëÇÑ Ä¡·á¹ýÀÌ °³¹ßµÇ°í ÀÖ´Ù. °¡¿ë¼ºÀÇ human leukocyte antigen-immunoglobulin fusion protein (HLA-Ig)¸¦ ±âÃÊÇÑ aAPCÀº DCsÀÇ ´ÜÁ¡À» º¸¿ÏÇÑ Ç׿øÁ¦½Ã¼¼Æ÷·Î½á DCsº¸´Ù ´õ¿í È¿°úÀûÀ¸·Î CTL¹ÝÀÀÀ» À¯µµÇØ ³¾ °ÍÀ¸·Î ±â´ëÇÑ´Ù. º» ÃѼ³¿¡¼­´Â ÀÌ DCsÀÇ ¿ªÇÒ°ú À̵éÀ» ÀÌ¿ëÇÑ ¾Ï Ä¡·á¹ý¿¡ ´ëÇؼ­ ³íÇÏ°í ±× °³¹ß °¡´É¼º¿¡ ´ëÇؼ­ ¾Ë¾Æº¸µµ·Ï ÇÏ°Ú´Ù.
All around the world, the rate of attack of cancer diseases has been going up and the number of cancer patients has been increasing every year. Cancer can be divided into malignant tumor and benign tumor according to its growth appearance. Many studies and experiments have been conducted and the various treatment are being created to find the way to care malignant. Dendritic cells (DCs), which is an agent of cancer treatments by using an immune reaction in our body, plays an important role to present by a tumor antigen to cytotoxic T-cell and help them to attack the tumor cell directly. However there are some defects of this therapy. Soluble human leukocyte antigen-immunoglobulin fusion protein (HLA-Ig) based artificial antigen presenting cell (aAPC) as the antigen presenting cell (APC) which is complement and overcome some of the limitations of dendritic cell-based vaccines and ex vivo expansion of human T cells is new method for cancer therapy. In this article, we are reviewing the role of DCs and the treatment with it, and searching for the possibility of the new development of immunotherapy for cancer.

Å°¿öµå

Dendritic cell, immunotherapy, cancer, vaccine
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
ÇмúÁøÈïÀç´Ü(KCI) 
ÁÖÁ¦ÄÚµå
ÁÖÁ¦¸í(Target field)
¿¬±¸´ë»ó(Population)
¿¬±¸Âü¿©(Sample size)
´ë»ó¼ºº°(Gender)
Áúº´Æ¯¼º(Condition Category)
¿¬±¸È¯°æ(Setting)
¿¬±¸¼³°è(Study Design)
¿¬±¸±â°£(Period)
ÁßÀç¹æ¹ý(Intervention Type)
ÁßÀç¸íĪ(Intervention Name)
Å°¿öµå(Keyword)
À¯È¿¼º°á°ú(Recomendation)
This article reviewed the role of DCs and the treatment with it, and searching for the possibility of the new development of immunotherapy for cancer.
¿¬±¸ºñÁö¿ø(Fund Source)
±Ù°Å¼öÁØÆò°¡(Evidence Hierarchy)
ÃâÆdz⵵(Year)
Âü¿©ÀúÀÚ¼ö(Authors)
´ëÇ¥ÀúÀÚ
DOI
KCDÄÚµå
ICD 03
°Ç°­º¸ÇèÄÚµå